TY - JOUR
T1 - No association between markers of systemic inflammation and endothelial dysfunction with Alzheimer’s disease progression
T2 - a longitudinal study
AU - on behalf of NILVAD Study Group
AU - van Setten, Arne
AU - Uleman, Jeroen F.
AU - Melis, René J.F.
AU - Lawlor, Brian
AU - Riksen, Niels P.
AU - Claassen, Jurgen A.H.R.
AU - de Heus, Rianne A.A.
AU - Segurado, Ricardo
AU - Kennelly, Sean
AU - Rikkert, Marcel G.M.Olde
AU - Howard, Robert
AU - Pasquier, Florence
AU - Börjesson-Hanson, Anne
AU - Tsolaki, Magda
AU - Lucca, Ugo
AU - Molloy, D. William
AU - Coen, Robert
AU - Riepe, Matthias W.
AU - Kálmán, János
AU - Kenny, Rose Anne
AU - Cregg, Fiona
AU - O’Dwyer, Sarah
AU - Walsh, Cathal
AU - Adams, Jessica
AU - Banzi, Rita
AU - Breuilh, Laetitia
AU - Daly, Leslie
AU - Hendrix, Suzanne
AU - Aisen, Paul
AU - Gaynor, Siobhan
AU - Sheikhi, Ali
AU - Taekema, Diana G.
AU - Verhey, Frans R.
AU - Nemni, Raffaello
AU - Nobili, Flavio
AU - Franceschi, Massimo
AU - Frisoni, Giovanni
AU - Zanetti, Orazio
AU - Konsta, Anastasia
AU - Anastasios, Orologas
AU - Nenopoulou, Styliani
AU - Tsolaki-Tagaraki, Fani
AU - Pakaski, Magdolna
AU - Dereeper, Olivier
AU - de la Sayette, Vincent
AU - Sénéchal, Olivier
AU - Lavenu, Isabelle
AU - Devendeville, Agnès
AU - Calais, Gauthier
AU - Crawford, Fiona
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Introduction: Systemic inflammation and endothelial dysfunction are potentially modifiable factors implicated in Alzheimer’s disease (AD), which offer potential therapeutic targets to slow disease progression. Methods: We investigated the relationship between baseline circulating levels of inflammatory (TNF-α, IL-1ß) and endothelial cell markers (VCAM-1, ICAM-1, E-selectin) and 18-month cognitive decline (ADAS-cog12) in 266 mild-to-moderate AD patients from the NILVAD study. We employed individual growth models to examine associations, potential mediation, and interaction effects while adjusting for confounders. Results: The average increase in ADAS-cog12 scores over all patients was 8.1 points in 18 months. No significant association was found between the markers and the rate of cognitive decline. Mediation analysis revealed no mediating role for endothelial cell markers, and interaction effects were not observed. Discussion: Our results do not support the role of systemic inflammation or endothelial dysfunction in progression in persons with AD.
AB - Introduction: Systemic inflammation and endothelial dysfunction are potentially modifiable factors implicated in Alzheimer’s disease (AD), which offer potential therapeutic targets to slow disease progression. Methods: We investigated the relationship between baseline circulating levels of inflammatory (TNF-α, IL-1ß) and endothelial cell markers (VCAM-1, ICAM-1, E-selectin) and 18-month cognitive decline (ADAS-cog12) in 266 mild-to-moderate AD patients from the NILVAD study. We employed individual growth models to examine associations, potential mediation, and interaction effects while adjusting for confounders. Results: The average increase in ADAS-cog12 scores over all patients was 8.1 points in 18 months. No significant association was found between the markers and the rate of cognitive decline. Mediation analysis revealed no mediating role for endothelial cell markers, and interaction effects were not observed. Discussion: Our results do not support the role of systemic inflammation or endothelial dysfunction in progression in persons with AD.
KW - ADAS-cog
KW - Alzheimer’s disease
KW - Biomarker
KW - Cytokine
KW - Endothelial dysfunction
KW - Longitudinal
KW - Mediation
KW - Mixed model
KW - Progression
KW - Systemic inflammation
UR - http://www.scopus.com/inward/record.url?scp=85200329575&partnerID=8YFLogxK
U2 - 10.1007/s11357-024-01294-x
DO - 10.1007/s11357-024-01294-x
M3 - Article
C2 - 39085534
AN - SCOPUS:85200329575
SN - 2509-2715
JO - GeroScience
JF - GeroScience
ER -